Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood May Be Necessary to Derive Clinical Benefit with Nivolumab Plus Relatlimab Over Nivolumab in Melanoma By Ogkologos - November 11, 2025 328 0 Facebook Twitter Google+ Pinterest WhatsApp Primary results of RELATIVITY-098 and translational evidence from RELATIVITY-098 and RELATIVITY-047 studies Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at Work as a Key Step towards Protecting the Cancer Workforce and Ensuring High-Quality... MOST POPULAR Healthy and Delicious Figs September 10, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Sotorasib November 22, 2021 Loss of Y Chromosome in Men Makes Bladder Cancer More Aggressive July 27, 2023 Έγκριση νέας επικουρικής θεραπείας για τον θετικά πρώιμο καρκίνο του μαστού June 24, 2019 Load more HOT NEWS Workout Wednesday – Leg Stretches Part 2 Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo... Capmatinib Shows Activity in Advanced NSCLC with a MET Exon 14... Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic...
